Meet the Women’s Health Fund.
The Big Picture
-
Recent years have seen a significant increase in both the number and size of dedicated women’s health funds, as well as a burgeoning interest from mainstream life science fund managers.
In the last three years, the largest dedicated fund in this space has gone from $40 million to over $250 million, and with the increase in capital, the exits continue to grow.
Among established managers, women’s health investments have even demonstrated an ability to outperform non-women’s health life sciences companies. Industry analytics indicate that the financial impact of women’s health innovations can surpass that of highly profitable GLP1s.
This is driven by scientific advancements into areas that are disproportionately, differently, or exclusively impacting women - areas that were previously unknowable because women were largely excluded from clinical trials until recent decades. Through this timely market building vehicle, investors gain unmatched visibility to both leading fund managers and the most promising developments in this fast growing field.
-
Conceptualized in partnership with industry leaders, along with a team of top performing life sciences fund managers investing across stages, sub-sectors, and regions, this market-building vehicle will operate as a standard fund of funds with direct co-investment.
-
The Women’s Health Fund is the first of its kind globally.
The portfolio will consist of 80% Life Sciences Funds, 20% Women’s Health Direct Co-investments.
Geographic Focus: US, Europe, and UK
Stage: Early-stage to late-stage for funds, commercial/growth for co-investments
Sub-sectors: therapeutics, med-tech, tech-bio, digital health
-
Allocated across a portfolio of leading life sciences funds totaling over $5 billion, this fund of funds provides access to managers with a combined $20 billion in assets under management. In a historic move to close the women’s health funding gap and support the inaugural fund of funds in the market, the management fees will be covered by visionary philanthropic foundations.
The Big Picture
-
Recent years have seen a significant increase in both the number and size of dedicated women’s health funds, as well as a burgeoning interest from mainstream life science fund managers.
In the last three years, the largest dedicated fund in this space has gone from $40 million to over $250 million, and with the increase in capital, the exits continue to grow.
Among established managers, women’s health investments have even demonstrated an ability to outperform non-women’s health life sciences companies. Industry analytics indicate that the financial impact of women’s health innovations can surpass that of highly profitable GLP1s.
This is driven by scientific advancements into areas that are disproportionately, differently, or exclusively impacting women - areas that were previously unknowable because women were largely excluded from clinical trials until recent decades. Through this timely market building vehicle, investors gain unmatched visibility to both leading fund managers and the most promising developments in this fast growing field.
-
Conceptualized in partnership with industry leaders, along with a team of top performing life sciences fund managers investing across stages, sub-sectors, and regions, this market-building vehicle will operate as a standard fund of funds with direct co-investment.
-
The Women’s Health Fund is the first of its kind globally.
The portfolio will consist of 80% Life Sciences Funds, 20% Women’s Health Direct Co-investments.
Geographic Focus: US, Europe, and UK
Stage: Early-stage to late-stage for funds, commercial/growth for co-investments
Sub-sectors: therapeutics, med-tech, tech-bio, digital health
-
Allocated across a portfolio of leading life sciences funds totaling over $5 billion, this fund of funds provides access to managers with a combined $20 billion in assets under management. In a historic move to close the women’s health funding gap and support the inaugural fund of funds in the market, the management fees will be covered by visionary philanthropic foundations.
Partners
Foundations
We have partnered with world leading visionary foundations focused on fueling sustainable market development. In a historic move, these foundations are covering the fund of fund fees and providing additional non-dilutive top-ups to eligible women’s health companies.
Strategics
The biopharma industry plans decades ahead to develop new therapies and treatments. They have long been experts at building the market, educating thought leaders and payers, evolving guidelines, and raising awareness before launching innovative molecules. We have partnered with some of the top market makers in the space to support commercial growth and exits.
Fund Managers
With a cumulative twenty billion dollars under management, the managers in our portfolio are known for their experience and their results. We are activating these venture capital leaders in women’s health, and supporting growth in their portfolio companies.
Thought Leaders
Building a market requires stakeholders from across the ecosystem. This includes researchers, policy makers, educators, media, health care providers, tech giants, and data leaders. We are partnering strategically and deliberately to ensure system wide growth.
Market Builders
Our Industry Advisory Board of Market Makers
Dallas Moreno
Organon
Sofia Pazari
Eli Lilly
Monet Goode
Ferring
Laurie Payton
Angelini
FAQs
-
We use the NIH definition. Women’s Health includes areas that differently, disproportionately, and exclusively impact women. For example, cardiovascular disease impacts women differently. Autoimmune disease impacts women disproportionately. And Endometriosis impacts women exclusively.
-
No. Our direct investments are sourced through our portfolio funds. These funds have been highly vetted and we encourage you to reach out to them if you are a match for their investment criteria.
-
New York City and London.